Superdrol Inj
Methyldrostanolone
Superdrol Injectable β Methyldrostanolone 40mg/ml by Dragon Pharma
Superdrol Injectable is Dragon Pharma's injectable formulation of Methyldrostanolone at 40mg/ml in MCT oil β the same active compound as Superdrol 10mg tablets, administered via intramuscular injection to bypass the first-pass hepatic metabolism that drives oral Superdrol's severe hepatotoxicity. For the complete compound background β including the methylated Masteron structure, prohormone history and mechanism β see the oral Superdrol page.
Also searched as: Injectable Superdrol, Methyldrostanolone injection, Superdrol Inj Dragon Pharma, injectable methasterone.
Why Injectable β The Hepatotoxicity Reduction Rationale
Injectable Methyldrostanolone is unusual β 17-alpha-alkylated compounds are almost exclusively oral because the alkylation's primary purpose is oral bioavailability. The injectable format addresses the oral form's core limitation:
- When oral Superdrol is swallowed, 100% of the absorbed dose passes through the liver (first-pass metabolism) before reaching systemic circulation. The 17-alpha-methyl group protects the compound from hepatic breakdown β but this resistance also means the compound is fully present in liver tissue at high concentration during this first pass, driving the severe hepatotoxicity
- When Superdrol is injected intramuscularly, it enters the bloodstream directly β bypassing the first-pass hepatic exposure entirely. The compound still reaches the liver via systemic circulation, but at the systemic blood concentration rather than the concentrated first-pass dose
- The result: injectable Methyldrostanolone produces significantly lower liver enzyme elevation than the oral form at equivalent doses β though hepatotoxicity is not eliminated (the compound still passes through the liver systemically) β it is meaningfully reduced
- This reduction in first-pass hepatic load is the primary reason for the injectable format's existence β it allows Superdrol's anabolic effects to be used with a more manageable hepatic safety profile
Oral vs Injectable Superdrol β The Practical Comparison
| Parameter | Superdrol Injectable (40mg/ml) | Superdrol Oral (10mg/tab) |
|---|---|---|
| Route | Intramuscular injection | Oral tablet |
| First-pass hepatic exposure | Bypassed β systemic delivery only | 100% first-pass through liver |
| Hepatotoxicity | Reduced β still present systemically | Severe β first-pass concentration |
| Bioavailability | Near-complete via IM | Moderate β first-pass metabolism |
| Convenience | Injection required | Oral tablet β most convenient |
| Dose precision | Volume-based β flexible | Tablet-based β 10mg increments |
| Same anabolic compound | Yes β identical active molecule | Yes |
Dosage and Administration
| Protocol | Dose | Frequency | Duration |
|---|---|---|---|
| Standard performance | 20β40 mg/day | Daily IM injection | 4β6 weeks maximum |
| Conservative start | 20 mg/day (0.5ml) | Daily | Assess hepatic response before escalating |
At 40mg/ml, a 0.5ml daily injection delivers 20mg; a 1ml injection delivers 40mg. The IM injection route is typically gluteal, vastus lateralis or deltoid β rotating sites daily. Because hepatotoxicity is reduced but not eliminated, cycle length is still strictly limited to 4-6 weeks, which is somewhat longer than the 3-4 week oral cycle maximum due to the reduced first-pass load. Liver enzyme monitoring remains essential throughout.
(edit with the Customer Reassurance module)
(edit with the Customer Reassurance module)
(edit with the Customer Reassurance module)
Comments (0)
Your review appreciation cannot be sent
Report comment
Report sent
Your report cannot be sent